Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
EMRIS Pharma is developing a novel small molecule-based topical drug aimed at preventing or treating skin toxicities—primarily papulopustular rash—caused by EGFR inhibitors used in cancer therapy. The approach is based on over a decade of research by leading Israeli scientists. The company’s lead program targets a significant unmet need, as up to 90% of patients treated with EGFR-targeted monoclonal antibodies experience these rashes, which can impact both quality of life and adherence to cancer treatment regimens. No clinical results have been published yet.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on EMRIS Pharma.